Humanigen seeks FDA approval for COVID-19 drug
Humanigen requested an emergency use authorization from the U.S. Food and Drug Administration (FDA) to use its drug lenzilumab in hospitalized COVID-19 patients. Read More
FDA issues EUA for GSK-Vir COVID-19 mAb treatment
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody (mAb) therapy sotrovimab from GlaxoSmithKline (GSK) and Vir Biotechnology. Sotrovimab is a treatment for mild to moderate COVID-19 in adults and pediatric patients over 12 years of age.

 Read More
FDA updates requirements for COVID-19 vaccine EUAs
The U.S. Food and Drug Administration (FDA) issued a new guidance document on May 25 that updates previously issued guidance and sets expectations for future COVID-19 vaccine emergency use authorizations (EUAs) during the pandemic. Read More
New research uncovers how SARS-CoV-2 hijacks RNA host proteins
A new study has uncovered the interactions that SARS-CoV-2 RNA establishes with the host cell proteins, many of which are fundamental for infection. The results, published in Molecular Cell on May 24, pave the way for the development of new therapeutic strategies for COVID-19 with broad-range antiviral potential. Read More
MilliporeSigma scales up lipid production for COVID-19 vaccines
MilliporeSigma announced that it has launched a new high-purity synthetic cholesterol product to meet demand for lipids, a component of messenger RNA-based vaccines and therapeutics such as those used for COVID-19. Read More
Waters launches SARS-CoV-2 LC-MS research kit
Lab equipment supplier Waters has debuted a new SARS-CoV-2 liquid chromatography–mass spectrometry (LC–MS) Kit for research use only. The kit uses an orthogonal analytical method to directly detect and quantify SARS-CoV-2 nucleocapsid peptides. Read More
Moderna vaccine 100% effective for teens
Moderna announced its phase II/III study of its COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint with no cases of COVID-19 observed in more than 3,700 participants ages 12 to 17 who received two doses of the vaccine. Read More
Pfizer to study pneumococcal, COVID-19 vaccine combo in older adults
Pfizer has launched a study that is investigating the coadministration of the company's pneumococcal vaccine (20vPnC) and its Pfizer-BioNTech COVID-19 vaccine in adults 65 and older. Read More
Moderna inks South Korean mRNA vaccine collaborations
Moderna has inked two memoranda of understanding agreements with South Korea for messenger RNA (mRNA) vaccine research and manufacturing in that country. Read More
EMA gives positive nod to GSK, Vir COVID-19 mAb
GlaxoSmithKline (GSK) and Vir Biotechnology today announced that the European Medicines Agency's (EMA) Committee for Human Medicinal Products has issued a positive scientific opinion following the referral of sotrovimab, a monoclonal antibody (mAb) to the EMA committee. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter